Loading…
← CockpitCompetitor Analysis › 300529.SZ Jafron Biomedical Co., Ltd. Class AOpen in the cockpit ↗

Jafron Biomedical Co., Ltd. Class A300529.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Medical Specialties

Leading Chinese maker of blood-purification devices and cartridges used to treat sepsis, liver failure and poisoning.

≈ A Chinese CytoSorbents (blood-purification therapy devices)Momentum leader 99
Mkt cap
$2.35B
US dollars, full cap
Free float
76%
of shares outstanding
$/day
$40.4M
20-day average traded
Fwd P/E
24.3×
forward earnings
ROIC−WACC
+22.0 pp
WACC 7.3%
Hurdle
+5 pp
Req g minus delivered
Next earnings
128 days
26 Mar 2027
Close · CNYCN¥19.82
1D-1.6%
1W-0.1%
1M+30.1%
3M+21.1%
6M+3.1%
YTD+0.8%
1Y-2.2%
ATR %3.2%
52w lowhigh7.3% off high

What Jafron Biomedical does

Leading Chinese maker of blood-purification devices and cartridges used to treat sepsis, liver failure and poisoning.

Places blood-purification machines in hospitals and earns mainly from the disposable cartridges used in every patient treatment, so sales follow treatment volumes rather than machine sales. Cartridge demand in China depends partly on hospital reimbursement and on approvals for new uses.

In one line: A Chinese CytoSorbents (blood-purification therapy devices).

Products and services

  • Hemoperfusion cartridges
  • Plasma exchange consumables
  • Blood-purification instruments

Customers

  • ICU/critical-care hospitals

Where it sits in the supply chain

  • Health Care
  • Medical devices
  • Blood purification (hemoperfusion)…

What could go right

  • ICU/critical-care blood-purification adoption

What could go wrong

  • Volume-based procurement price cuts

Moat: narrow (IP / patents, installed base). Patented adsorbent cartridge technology paired with an installed instrument base.

Headquarters: Zhuhai, Guangdong, China · Founded: 1996 · Employees: 3,093

Named competitors

Jafron Biomedical at a glance

Size Jafron Biomedical (300529.SZ) is a China Health Care company (Medical Specialties) with a market value of $2.35B, the 1021st largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥19.82 on 18 Nov 2026.

Performance Over six months the shares gained 3.1%, against -0.1% for the median peer and -20.0% for the China market (cap-weighted) — 9th highest of 20 in its peer set.

Growth Revenue grew 1.4% over the last twelve months (peer median +7.5%); the operating margin is 36.7% (peer median 10.7%).

Valuation It trades at 24.3× forward earnings against a peer median of 24.2× (9th most expensive of 18).

Price implies For today's price to make sense, revenue must grow about 6% a year for seven years (Req g). Recent delivered growth is +1%, so the hurdle is +5 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 22.0 points above its cost of capital (7.3% WACC).

Next results Next results expected around 26 Mar 2027 (exchange calendar; dates can move).

Relative performance

809010011021 May 202621 Aug 202618 Nov 2026300529.SZ 104Peer median 101
Six months, rebased to 100: Jafron Biomedical against the median of its 20 peers (local-currency closes).

Jafron Biomedical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥2.07BCN¥1.99BCN¥2.65BCN¥1.90BCN¥2.46B
Revenue growth—-25%+39%-23%—
Gross profitCN¥1.65BCN¥1.49BCN¥2.07BCN¥1.45BCN¥1.98B
EBITDAn/aCN¥846MCN¥1.14BCN¥592MCN¥1.01B
Net incomeCN¥654MCN¥533MCN¥820MCN¥436MCN¥890M
Free cash flowCN¥760MCN¥602MCN¥858MCN¥676MCN¥430M
Capital expenditureCN¥179MCN¥173MCN¥235MCN¥247MCN¥476M
Total debtCN¥1.30BCN¥1.36BCN¥1.53BCN¥1.84BCN¥1.31B

Quarterly statements and history in the cockpit →

Jafron Biomedical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%-25%0%+25%EKTA-B688029NEOG0029012276MOVEEBOMETNDRW86951ESTAOBCKVCYTBONEXCELCATRCMEDSKAN300529.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Jafron Biomedical is the large dot.

Fundamentals: revenue growth against valuation

0%+20%0×100×200×EKTA-B688029NEOG0029012276EBOMETNDRW86951VCYTBONEXATRCMEDSKAN300529.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Jafron Biomedical is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%EKTA-B6880290029012276EBODRW86951OBCKVCYTBONEXATRCSKAN300529.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Jafron Biomedical is the large dot.

Jafron Biomedical competitors and peer comparison

Head to head with its named competitors (300529.SZ vs CTSO vs FME.DE)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Jafron Biomedical 300529.SZ$2.35B+3%+1%37%24.3×6.1%
Cytosorbents CTSOn/a-41%n/an/an/an/a
Fresenius Medical Care FME.DE$11.2B+3%-1%11%9.5×-4.8%

How Jafron Biomedical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Jafron Biomedical against its 20 peers (data as of 18 Nov 2026)
Measure300529.SZPeer medianRank in peer set
1-month return+30.1%-1.6%2nd highest of 21
6-month return+3.1%-0.1%9th highest of 20
Distance from 52-week high-7.3%-24.0%6th highest of 21
Revenue growth (TTM)+1.4%+7.5%6th lowest of 20
Operating margin36.7%10.7%highest of 20
Forward P/E24.3×24.2×9th most expensive of 18
Growth the price implies (Req g, 7 yrs)6.1%11.3%5th least demanding of 13
Growth delivered (Del g)+0.6%+11.1%2nd lowest of 13
Hurdle (Req g minus delivered)+5.5 pp-5.1 pp4th most demanding of 13
ROIC minus cost of capital+22.0 pp-0.6 pp2nd highest of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Jafron Biomedical 300529.SZChina$2.35B+3%+1%37%24.3×6.1%+0.6%
Elekta EKTA-B.STSweden$2.35B0%-7%6%15.3×10.7%+4.0%
Micro-Tech (Nanjing) 688029.SSChina$2.33B0%+6%18%28.1×11.9%+19.2%
Neogen NEOGUnited States$2.42B+25%0%0%32.6×n/an/a
Double Medical Technology 002901.SZChina$2.43B-2%+13%26%24.2×7.6%+10.4%
Shanghai Conant Optical 2276.HKHong Kong$2.25B-17%+8%29%22.1×-1.1%+14.1%
Medacta MOVE.SWSwitzerland$2.48B-28%+8%15%24.0×n/an/a
EBOS EBO.AXAustralia$2.50B+7%+3%3%15.7×4.7%+6.8%
Metall Zug METN.SWSwitzerland$2.19B+20%0%-10%139.8×n/an/a
Draegerwerk AG & Co. KGaA DRW8.DEGermany$2.13B+25%+5%7%10.2×-10.2%+0.4%
JEOL 6951.TJapan$2.12B-2%-15%12%15.5×22.2%+10.2%
Establishment Labs ESTAUnited States$2.11B+1%+38%-7%n/an/an/a
Ottobock SE & Co. KGaA OBCK.DEGermany$2.65B-30%+5%17%12.3×-1.2%+8.0%
Veracyte VCYTUnited States$2.06B-43%+18%16%17.1×18.0%+34.5%
Bonesupport BONEX.STSweden$2.06B+21%+25%25%61.5×12.6%+45.4%
Celcuity CELCUnited States$2.73B-60%n/an/an/an/an/a
COMET COTN.SWSwitzerland$2.78B-15%-3%6%32.8×n/an/a
AtriCure ATRCUnited States$2.82B+91%+14%3%212.4×54.2%+20.9%
Medartis MED.SWSwitzerland$1.86B+47%+30%2%72.8×n/an/a
SKAN SKAN.SWSwitzerland$1.85B+40%+9%11%49.5×13.8%+11.7%
Molbio Diagnostics MOLBIO.NSIndia$1.85Bn/a+35%17%n/an/an/a

Questions

Who are Jafron Biomedical's main competitors?
Named competitors: CytoSorbents (CTSO), Fresenius Medical Care (FME.DE), B. Braun (private) (private or unlisted). The cockpit's measured peer set (industry) also includes Elekta (EKTA-B.ST), Micro-Tech (Nanjing) (688029.SS), Neogen (NEOG), Double Medical Technology (002901.SZ), Shanghai Conant Optical (2276.HK), Medacta (MOVE.SW).
Is Jafron Biomedical expensive compared with its peers?
On forward p/e it trades at 24.3× against a peer median of 24.2×, 9th most expensive of 18 in its peer set. For today's price to make sense, revenue must grow about 6% a year for seven years (Req g). Recent delivered growth is +1%, so the hurdle is +5 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Jafron Biomedical stock performed?
Over six months to 18 Nov 2026 the shares returned +3.1% against -0.1% for the median peer; over one year -2.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.